5 December 2023PharmaLiz Hockley

US biotech wins review of rival’s endocrine patents after Vidal intervention

USPTO director remanded case back to PTAB after it denied post-grant review of Spruce patents | Judges determined likelihood of claims being unpatentable due to prior art and lack of written description.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

SK Biopharmaceuticals settles epilepsy generic dispute

20 August 2026 A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.

Pharma

Vanda revives challenge over braille-free label on generic sleep disorder drug

19 August 2026 Questions over braille on a generic sleep disorder drug label will face fresh scrutiny after an appeals court found fault with the FDA’s approach.

Pharma

Novartis scores UK win in high-stakes Entresto fight

14 August 2026 Pressure for generic manufacturers of the blockbuster heart drug Entresto is mounting as the Swiss pharma company secures a win over a challenge to its UK patent protection.

More features

10x Genomics dealt major blow in sequencing fight

SK Biopharmaceuticals settles epilepsy generic dispute

Vanda revives challenge over braille-free label on generic sleep disorder drug

Abbott fends off Chinese rival’s patent challenge at UPC

Former head of litigation at Nokia returns to Bird & Bird

Former USPTO acting director takes the helm at C4IP

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

Novartis scores UK win in high-stakes Entresto fight

US biotech wins review of rival’s endocrine patents after Vidal intervention

More on this story

Editor's picks

Editor's picks

More features